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In Britain, the life-time risk of lung cancer in men who
smoke 20 or more cigarettes per day is about 15%. That
most smokers never develop lung cancer has promoted
interest in the role of host factors. While chance, other
environmental factors and the competing effect of other
diseases, some of which are also smoking related, are all
likely to affect individual lung cancer risk, genetic factors
may also be important. This review examines the evidence for
genetic predisposition to smoking related lung cancer.
The review concentrates on the numerous metabolic
studies that have sought differences between individuals in
the genetic control of biochemical pathways that could be
involved in the metabolism of carcinogens in tobacco smoke.
Insights gained are likely to have wider implications for other
environmental carcinogens. Other studies that have sought
simple evidence, such as familial clustering or associations of
lung cancer with blood group, HLA and other naturally
occurring antigens, are also examined. The field of
chromosomal abnormalities in lung cancer and the difficulties
in interpreting them is reviewed only briefly, since this area
may not directly relate to tobacco smoking and has been
reviewed elsewhere (Birrer & Minna, 1988). Various sources
of bias important in the interpretation of the metabolic
studies in particular are outlined. Future research is likely to
be dominated by the recent advances in molecular genetics
that offer the possibility of circumventing bias by the direct
identification of genes, but at present this is possible only to
a limited extent.
Familial clustering of lung cancer cases
Familial clustering of a cancer (or indeed of any disease) is
an insensitive indicator of genetic predisposition. Peto (1980)
and Bodmer (1986) have pointed out that a cancer can have
a major genetic component yet show no detectable familial
clustering. The ratio of the incidence of the cancer in
relatives of known cases to that in age-matched controls is
the only measure of familial clustering (in the absence of a
marker). This ratio will be much smaller than the ratio of the
incidence in genetically susceptible to non-susceptible individ-
uals, which is the direct measure of the magnitude of the
genetic effect. It is a question of dilution - not all patients
with cancer will be genetically susceptible individuals, fewer
of their relatives will be, and tne general population contains
susceptibles as well as non-susceptibles. The effect of such
dilution is greater than may intuitively be assumed. Using the
model of a single autosomal gene that affects cancer risk, and
assigning various values for gene frequency and the increased
risk of cancer in genetically susceptible individuals, Peto
(1980) showed that even with a very large cancer risk in
susceptibles, the incidence of cancer in relatives will generally
be increased by no more than 1.5-3-fold. It is difficult in a
family study to show that such a modest increase could not
be due to chance, shared exposure or other bias.
Five studies have examined lung cancer incidence in
relatives of cases, but three (Tokuhata & Lilienfeld, 1963b;
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Lynch et al., 1982, 1986) did not take into account the fact
that relatives of lung cancer patients are themselves more
likely than average to be smokers (Tokuhata & Lilienfeld,
1963a) and so have increased lung cancer risk. Tokuhata and
Lilienfeld (1963a) and Ooi et al. (1986) separately compared
smoking and non-smoking relatives and their results are
summarised in Table I. Both studies found about a 3-fold
increased lung cancer incidence in both smoking and non-
smoking relatives of lung cancer patients. This could corres-
pond to a much larger genetic effect if it were real, but a
relative risk of three could readily be produced by bias.
Possible sources of bias in these studies include familial
sharing of the same environment (e.g. asbestos exposure),
family history recall bias among lung cancer patients com-
pared to controls (independent confirmation of causes of
death in relatives was often incomplete), and the possibility
that relatives of cancer patients may on average be heavier
smokers than control relatives and also may be more likely
to claim falsely to be non-smokers (smokers who deny the
habit may constitute a small minority of all 'non-smokers'
but will contribute substantially to their lung cancer
incidence). Consistent with the latter possibility is the obser-
vation of higher mortality from non-malignant respiratory
diseases among both 'smoking' and 'non-smoking' relatives
of cases (Tokuhata & Lilienfeld, 1963a).
The increased lung cancer incidence in relatives of cases is
therefore consistent with any interpretation, from a large
genetic effect to bias with no genetic effect at all. To demon-
strate genetic predisposition to lung cancer a marker
associated with the predisposition must be identified.
Reports of clustering of cancer in individual families are
generally of limited value, but the report of Paul et al. (1987)
of alveolar cell carcinoma (which is not smoking related)
developing in three brothers suggests genetic predisposition
because of the extreme rarity of this cancer. While such
familial clustering need not be genetic (it might be a viral
infection), the three brothers shared HLA-A28 (population
frequency 5%) while a fourth unaffected sibling lacked HLA-
A28. Studies in mice suggest autosomal dominant inheritance
of alveolar cell carcinoma (Paul et al., 1987). Joishy (1977)
reported simultaneous onset of alveolar cell carcinoma in
identical twins.
NaturaUy occurring antigens and chromosomal abnormalities as
genetic markers of lung cancer risk
The distribution ofABO and Rh blood groups in lung cancer
cases was compared to the general population in eight studies
(Aird et al., 1954; McConnell et al., 1955; Parker & Walsh,
1958; Rennie & Haber, 1961; Jakoubkova & Majsky, 1965;
Ashley, 1969; Roberts et al., 1988; Roots et al., 1988). A
deficit of group 0 in lung cancer observed in the last study
was not supported by the other seven, and various associa-
tions of blood groups with certain histological types and with
proximal tumours reported by Ashley (1969) were again not
present in the other studies. Beckman et al. (1986) reported
the distribution ofhaptoglobin groups in lung cancer patients
and controls and reviewed three similar studies - an associa-
tion in their own study was not present in the others. Of five
studies that have sought associations between HLA antigens
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Table I The incidence of lung cancer in first degree relatives of cases in two studies, categorising relatives by smoking status
Non-smoking relatives Smoking relatives
Number with Expected number Expected number
lung cancer (from control Number with (from control
relatives) Ratio lung cancer relatives) Ratio
Ooi et al. (1986) fathers or
(spouse controls) brothers 3 2.1 65 27.0
mothers or
sisters 11 2.4 11 2.6
Total 14 4.5 3.1 76 29.6 2.6
Tokuhata & fathers or
Lillienfeld (1-963a) brothers 4 0 23 10.1
(neighbourhood mothers or
controls) sisters 8 3.2 0 0
Total 12 3.2 3.8 23 10.1 2.3
and lung cancer, two have observed the same association, the
HLA-B12 antigen being reported by Markman et al. (1984)
in 52% of 50 cases of small cell carcinoma, 26% expected
(P<0.0001; significant even when the large number of com-
parisons was considered), and by Tongio et al. (1982) in 36%
of 84 cases of squamous cell carcinoma, 24% expected
(P<0.05). However, Sengar et al. (1977) and Ford et al.
(1981) found the same HLA antigen to occur in fewer than
expected patients with lung cancer; this apparent contradic-
tion can only be resolved by further observation. No other
association was common to two or more ofthese four studies
and that of Takasugi et al. (1973). Heighway et al. (1986)
observed that a specific allele (a4 Aa-ras) occurred in 19/66
(29%) patients with non-small cell lung cancer but 15/101
(15%) controls (P=0.03).
These types of association are sought without prior
hypothesis, and when many comparisons are made, some will
be statistically significant by chance. Some of the above
associations may be real and important, but confirmation in
further studies is required. Associations of blood group and
HLA antigens with cancer risk in populations must represent
linkage disequilibrium, and Bodmer (1986) has shown that
such associations of two unrelated genes on the same
chromosome could have persisted (in the absence of natural
selection) only with extremely close linkage, with recombina-
tion fraction approaching 0.1%.
Various chromosomal abnormalities (deletions and rear-
rangements) have been observed in lung cancer, small cell in
particular, notably the deletion of chromosome 3p. Birrer
and Minna (1988) have reviewed these and other aspects of
molecular genetics in lung cancer. There is a general difficulty
in determining whether chromosomal abnormalities preceded
the cancer or were produced by the genetic instability result-
ing from malignant transformation. The latter appears less
likely in the study of Yokota et al. (1987), testing both
cancerous and normal lung tissue from 47 patients against
markers for 24 restriction fragment length polymorphisms. A
high incidence ofallelic deletions was found in small cell lung
cancer at three chromosomal loci (3p, 13q and 17p). The
putative retinoblastoma (Rb) gene is located on 13q, and this
gene is associated with small cell lung cancer by the finding
of abnormalities of its structure and expression (Harbour et
al., 1988) and by a case report (Leonard et al., 1988).
Metabolismofforeignchemicals(includingpotentialcarcinogens)
It is usually metabolites of environmental carcinogens, rather
than the parent compounds, that initiate a cancer (Miller,
1978; Farber, 1981), and many studies have sought
genetically determined differences between individuals in the
extent to which metabolities are generated. The metabolism
to water soluble products is common to many chemicals
foreign to the body and exists to facilitate excretion, since the
parent compounds, being highly fat soluble but hydrophobic,
may be very slowly excreted. There are two phases to the
metabolism (Nebert, 1981), summarised in Figure 1. In phase
I a 'handle' is attached to the molecule, commonly by inser-
tion of an oxygen atom, to form a reactive intermediate
substance, which in phase II is conjugated though the 'han-
dle' with an endogenous compound to become water-soluble
and readily excreted.
Phase I mono-oxygenation
Phase I mono-oxygenation is performed by the cytochrome
P-450 microsomal enzyme system, present in many tissues
including lung (Gonzalez et al., 1986). (The colour in the cell
that the name implies is imparted by haeme, a pigment (P)
with peak optical absorption wavelength of 450 nm.) Among
the many structurally diverse substrates of the P-450 enzymes
are various combustion products in tobacco smoke including
polycyclic aromatic hydrocarbons and nitrosamines. The
system is probably coded for by at least 50 genes (Wolf,
1986). It is classified (arbitrarily by structural similarity
between P-450 proteins) into families and sub-families of
P-450 enzymes, but their substrate specificities overlap and
different systems of nomenclature exist (Wolf, 1986; Nebert
et al., 1987). Some sub-families exhibit detectable activity
only after 'induction' (a period of exposure to certain foreign
compounds that induce the production of a large number of
copies of the enzyme); preferential induction of specific isoen-
zymes active against the inducing agent itself is common.
(The greater tolerance to alcohol of regular drinkers than
occasional drinkers is an example.) Other P-450 sub-families
are constitutively expressed, exhibiting activity without induc-
tion.
Phase II conjugation
After phase I mono-oxygenation, foreign compounds are
sometimes sufficiently water soluble to be excreted, but more
commonly they are first made more water soluble by con-
jugation with endogenous compounds. Examples are the con-
jugation ofbenzo[a]pyrene with glucuronic acid, sulphate and
glutathione (Figure 1), and the acetylation of the drug
isoniazid (discussed below).
Production ofcarcinogen-DNA adducts
Oxygenated phase I intermediate substances on occasion do
not proceed to conjugation but bind covalently and non-
enzymatically with centres on nucleic acids and proteins, and
such a combination with DNA may initiate carcinogenesis
(Miller, 1978; Farber, 1981; Miller & Miller, 1983; Pelkonen
& Nebert, 1982). The generation of such carcinogen-DNA
adducts might be increased, with resultant predisposition to
lung cancer, either by genetically determined increased mono-
oxygenating activity or by genetically determined reduced
conjugating (phase II) activity (Figure 1).GENETIC PREDISPOSITION TO LUNG CANCER 197
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Figure 1 Metabolism of foreign chemicals, and specifically polycyclic aromatic
Metabolic markers of genetic predisposition to lung cancer
Metabolic markers of genetic predisposition to lung cancer
are sought under the assumptions that the carcinogen(s) in
tobacco smoke, like most carcinogens, will initiate cancer
only after metabolism, and that there is important genetically
determined variation (and perhaps polymorphism) in that
metabolism. While the metabolism of many compounds can
be controlled by a number of enzymes, each with its own
environmental as well as genetic determinants of activity, the
effect of one gene may be of an order of magnitude larger
than that of the environmental and other genetic factors, so
as to produce large variation (10-100-fold) between individ-
uals in the activity of an entire metabolic pathway (Nebert,
1981), and so be rate-limiting. An example is the autosomal
recessive defect that renders some individuals slow
acetylators of isoniazid and other drugs, and slow acetylators
have increased risk of occupational bladder cancer (Cart-
wright et al., 1982).
Metabolic markers of lung cancer risk, like other markers,
are sought without prior hypothesis, in that it is not known
which, or how many, of the large number of experimentally
carcinogenic tobacco smoke constituents actually cause lung
cancer in human smokers. Lung cancer risk might correlate
strongly with the activity of one metabolic pathway, or
weakly with several. Many studies have sought differences
between lung cancer patients and controls in the activities of
certain cytochrome P-450 sub-families. Preliminary studies
have also examined phase II conjugating enzymes. Metabolic
activity is measured usually in lymphocytes in vitro or in the
liver in vivo and assumed to correlate within individuals with
activity in the bronchial mucosa where access is more
difficult.
All studies to date of metabolic markers in lung cancer
have been case-control in design. Thus if case-control
metabolic differences are found they might not be genetically
determined but could be a consequence of the cancer or its
treatment. Metabolic effects could be produced by: (a)
analgesics, sedatives and other drugs more likely to be taken
by lung cancer patients than controls; (b) factors related to
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hospital admission or illness, such as recent changes in diet,
caffeine and alcohol consumption or bed rest; (c) a metabolic
effect of cancer; (d) other consequences of cancer, such as
weight loss, liver metastases and hypoxia; and (e) recent
change in smoking habit (since lung cancer patients often
reduce or stop smoking at the time of clinical presentation
but are matched with controls by long-term smoking). Con-
versely, negative studies could be misleading if the metabolic
assay was too indirect or insensitive to show a real effect.
Studies of aryl hydrocarbon hydroxylase activity in lung cancer
Rationale
The metabolism of benzo[a]pyrene and other polycyclic
aromatic hydrocarbons (PAHs) found in tobacco smoke has
been extensively studied ('aromatic' hydrocarbons have
benzene-like unsaturated six-membered carbon rings). The
overall metabolism is complex - for benzo[a]pyrene there are
several pathways of variable activity (simplified in Figure 1)
with over 40 metabolites in all (Gelboin, 1980). Epoxides
(three-membered cyclic ethers formed by one oxygen and two
carbon atoms) or, more specifically, arene oxides are reactive
intermediate metabolites of PAHs that have been shown
experimentally to bind to DNA causing mutation and malig-
nant transformation of cells (Gelboin, 1980; Conney, 1982;
Pelkonen & Nebert, 1982). Cultured human bronchus can
produce carcinogen-DNA adducts (Harris et al., 1980).
Metabolic studies cannot measure iso-enzyme specific PAH
mono-oxidation; what they have measured is the overall
production of certain mono-oxygenated metabolites of
benzo(a]pyrene (a PAH), an activity called aryl hydrocarbon
hydroylase (AHH) ('aryl' being synonymous with 'aromatic').
Most induced AHH activity is iso-enzyme specific and per-
formed by one cytochrome P450 sub-family, called P1450 in
one nomenclature, but other sub-families with different
genetic and environmental determinants also contribute
variably (Lang & Nebert, 1981; Negishi & Nebert, 1979).
AHH activity can ethically only be measured in vitro, because
conjupted waler
soluble products
(rapidly excretedl
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the direct administration of PAHs as inducers and substrates
may be carcinogenic.
Methodology
Different types of assay measure different metabolites of
benzo[a]pyrene; many are produced. Most studies have used
a simple fluorometric assay that measures 3-OH and 9-OH
(alkali soluble) metabolites. These metabolites are not
themselves carcinogenic; the extent of their formation is
assumed to correlate with that of the epoxide that is, but this
is not proven. The amount of metabolite measured is divided
by the number of cells, or by the measured amount of DNA
or cytochrome C as indices of the number of cells. The assay
is done with and without prior induction with 3-
methylcholanthrene or other PAHs. AHH activity is highly
inducible, but non-induced activity is low, and the term
'inducibility' (or 'fold induction') refers to the ratio of the
two. Induced and non-induced activity represent different
cytochrome P-450 sub-families (Meehan et al., 1988b; Arnott
et al., 1979). Which, if any, of these measures of AHH
activity is most relevant to the in vivo situation is uncertain,
as is the relationship of the maximally induced AHH activity
which is measured to 'usual' AHH activity in smokers. Some
studies report induced AHH activity, others report
inducibility.
Jett et al. (1978) and others have used a radiometric assay
which measures water soluble metabolites of radiolabelled
benzo[a]pyrene by their radioactivity. These metabolites also
are not themselves carcinogenic, and the technique measures
only induced levels of AHH. A third technique has measured
radiolabelled benzo[a]pyrene metabolite binding to macro-
molecules (DNA or protein). This assay might be expected to
provide a more direct measure of those metabolites directly
involved in mutagenesis and carcinogenesis.
Assay limitations
Reproducibility of the fluorometric assay in particular is
limited, and influenced by many extraneous factors including
length of incubation, starting cell density, duration of
storage, season and geographical latitude (Gurtoo et al.,
1977; Korsgaard & Trell, 1978; Cantrell et al., 1973; Arnott
et al., 1979). There are further problems in lymphocyte AHH
assays. To provide detectable amounts of enzyme, prolifera-
tion of lymphocytes must first be stimulated by mitogens: the
extent of proliferation varies between individuals, declines
with age, may be influenced by cancer and depends on
additional technical factors such as lot of fetal calf serum and
nature of mitogen. The proportions of the different types of
mononuclear cells vary.
Genetic control ofAHH activity
Mice The earlier work of Nebert et al. (1972) identified
some inbred strains of mice where AHH activity was induci-
ble in all individuals, some strains where it was never induci-
ble and other strains that included inducers and non-
inducers. Breeding experiments between the strains showed
that induction was determined by a single genetic locus,
termed the Ah locus (for aryl hydrocarbon). The observation
that in wild mice (and humans) induction is continuously
distributed and not 'all or nothing' suggested that other
genes were also important but did not differ between the
inbred mice strains studied.
More recent work has shown that the Ah locus is a
regulatory one that determines the induction of many struc-
tural loci controlling enzymes responsible for foreign
compound metabolism (Gonalez et al., 1986). The Ah locus
has been assigned to chromosome 12 in the mouse (Cobb et
al., 1987). Its major product is a cytosolic receptor that binds
inducing compounds, then migrates to the nucleus (Okey et
al., 1980). Increased cytochrome P,-450 mRNA synthesis
follows (Israel & Whitlock, 1984). The conjugating enzymes
glutathione transferase and UDP glucuronyl transferase
(Figure 1) are also likely to be induced (Lang & Nebert,
1981). Only one structural locus, mapped by Hildebrand et
al. (1985) to chromosome 9, appears to influence cytochrome
P1-450 activity in mice (Hankinson et al., 1985). Other
cytochrome P-450 sub-families also contribute to induced
AHH activity as stated above. Constitutive (non-induced)
AHH activity in mice (much lower than induced activity) has
been mapped to a different P-450 structural locus, on
chromosome 19 (Meehan et al., 1988b).
Human studies Cell culture experiments in humans have
identified the regulatory Ah locus and assigned it to
chromosome 2 (Wiebel et al., 1981; Ocraft et al., 1985).
Amsbaugh et al. (1986) have isolated the human PI-450
structural locus. As in mice, other cytochrome P-450 sub-
families also contribute to AHH activity, notably P-450-2C
(Shimada et al., 1986), with structural locus on chromosome
10 (Meehan et al., 1988a).
Three family studies have suggested an important effect of
a single gene on AHH activity. Kellerman et al. (1973a, b)
and Trell et al. (1985) both reported a trimodal distribution
with low inducibility being dominant and heterozygotes being
distinguishable by intermediate AHH activity. Gahmberg et
al. (1979) reported a bimodal distribution, with high
inducibility (15% of the population) being dominant. How-
ever, all other studies have observed unimodal distributions
of AHH activity, in keeping with polygenic control. In three
twin studies (Atlas et al., 1976; Okuda et al., 1977; Paigen et
al., 1978), intra-pair differences in AHH induction for
monozygous twins were similar to that of the same individual
measured twice, but for dizygous twins were small for most
pairs but larger for a few, suggesting that the number of
genes influencing induced AHH activity is fairly small but
exceeds one. Emery et al. (1978) stated that their unpublished
family study favoured polygenic inheritance.
All studies concur that there is large variation (which could
be genetically determined) only in induced AHH activity.
Non-induced activity shows little variation, and as mentioned
above is likely to represent a different cytochrome P-450
family.
Environmental determinants ofAHH activity
Many environmental factors influence in vivo AHH activity,
and several may bias case-control studies in lung cancer.
Cigarette smoking increases AHH activity in the lung and in
tissues distant from the lung - both baseline and induced
levels are higher in smokers than non-smokers (Conney,
1982; Cantrell et al., 1973). Other factors associated with
cancer that may influence AHH activity include serum
cholesterol (Korsgaard & Trell, 1978) and asbestos exposure
(Snodgrass et al., 1981), while several dietary factors (which
may change with hospital admission) also affect AHH
activity (Conney, 1982).
Evidencefor an association between AHH activity and lung
cancer
Animal evidence Kouri et al. (1980) showed in laboratory
mice that intratrachael administration of 3-methylcholan-
threne (3-MC), a PAH, produced lung cancers in 38 (45%)
of 84 mice that were Ah dominant (having high AHH
activity, 40-60 unitsg-' liver), but in only two (8%) of 25
Ah recessive mice (7-11 units of AHH activityg' liver)
(P = 0.001). Pre-cancerous lesions were also common in the
Ah dominant mice. In a control group of 46 Ah dominant
AHH mice given no 3-MC, no tumours developed. Because
of 3-MC toxicity only about 20% of treated mice survived
one year to be examined for presence of lung cancer, but this
ought not to introduce bias.
Human lung tissue studies Insufficient bronchial mucosa can
be obtained at bronchoscopy for assay purposes and lung
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required. This has limited numbers, particularly of controls,
in the studies, and made it difficult to match cases and
controls by age, smoking habit etc. Both the cancer in the
cases and the non-malignant diseases in the controls may
alter AHH activity. Also, not surprisingly, the effect of smok-
ing on AHH activity in the lung is greater than in remote
tissues (Cantrell et al., 1973). AHH activity as measured in
human lung tissue is one or two orders of magnitude lower
than in the rat (Oesch et al., 1980; Karki et al., 1987); the
reason is uncertain.
The studies of human lung tissue are essentially negative.
Table II summarises four case-control comparisons of AHH
activity in lung tissue. One (Oesch et al., 1980) found higher
activity in cases (statistically significant for non-smokers but
not smokers) but the difference was only about 2-fold and
might readily have been produced by bias. The three other
controlled studies were negative. Also, McLemore et al.
(1978b) reported no difference between lung cancer cases and
controls in AHH activity in pulmonary alveolar macrophages
obtained by lavage. In three uncontrolled studies (Harris et
al., 1976; Cohen et al., 1979; Sabadie et al., 1981), AHH
activity in cultured bronchus or peripheral lung tissue of
patients with lung cancer showed, like the controlled studies,
wide unimodal distribution (20-, 44- and 75-fold variation
between individuals) that was not suggestive of a substantial
tendency for lung cancer to cluster in smokers with com-
paratively high AHH activity.
Human lymphocyte studies Most human studies have
measured AHH activity in peripheral blood lymphocytes
rather than lung tissue because of ease of sampling. Correla-
tion between AHH activity in lymphocytes and lung tissue
was high in seven subjects without lung cancer (r = 0.98,
McLemore et al., 1978a) but was poor in lung cancer
(r = 0.01, n = 7, McLemore et al., 1978a; r=0.62, n = 30,
Karki et al., 1987).
The results of the case-control comparisons oflymphocyte
AHH activity in lung cancer conflict. They are summarised in
Table III. The first such study (Kellermann et al., 1973a, b),
widely cited, reported that high and intermediate AHH
inducers, 9% and 46% of the population, had 37 and 16
times respectively the lung cancer risk of low inducers (45%
of the population). Subsequent studies did not reproduce
these results, but some later studies have also reported higher
AHH inducibility in lung cancer cases than controls, and of
all the studies (Table III) about half have measured higher
AHH inducibility in lung cancer patients than controls; the
others show little or no difference. There must be bias in
either the positive or negative studies. The discrepancy can-
not easily be attributed to insensitive assay technique in the
negative studies as their reproducibility was no lower and
some of them have demonstrated other associations (e.g.
correlation between AHH activity in lymphocytes and lung
tissue, difference between smokers and non-smokers).
The difference quoted in all but two of the 'positive'
studies is a higher inducibility ratio which often reflects lower
non-induced rather than higher induced AHH activity in
cases, and there does not appear to be important genetically
determined variation in the former. Moreover, AHH activity
in cases, as discussed above, could be affected by factors
related to cancer, illness, age and smoking. The most convin-
cing 'positive' study is that of Kouri et al. (1982), who
overcame some technical assay problems, matched cases and
controls as closely as possible, assayed blindly, and found
induced AHH activity to be about twice as high on average
in cases as controls, and higher in 14 of the 21 cases than in
any of the controls. However, some environmental
differences, particularly a biological effect of the cancer, can-
not readily be controlled, and non-carcinogenic metabolites
were measured. No other group has attempted to reproduce
the result using the same technique. Another study that
attempted to reduce bias by selecting cases with resected
cancer, and matching for medication, was negative (Ward et
al., 1978). In the two studies that measured macromolecular
binding (a more direct measure of the carcinogenic
metabolites), binding was actually less in lung cancer cases
than in controls (P = 0.03) in one (Jett et al., 1979) and there
was no significant difference in the other (Rudiger et al.,
1980).
Antipyrine as a drug marker of phase I mono-oxidation
Rationale andmethodology
Associations of drug metabolism with lung cancer are sought
as a convenient in vivo means of exploring metabolic predis-
position to cancer, since the same cytochrome P-450 sub-
family could metabolise both a drug and a carcinogen.
Antipyrine (AP) was the first drug to be tested in this way.
It is a salicylate-like drug whose half-life or plasma clearance
provides a pharmacological index of the activity of certain
cytochrome P-450 drug oxidising enzymes in the liver. It was
tested as a marker drug for lung cancer risk because, in
humans, its half-life correlates with benzo[a]pyrene hydrox-
ylation. This was shown by Kapitulnic et al. (1977) in
homogenates from 32 cadaver livers (r = -0.85, although the
correlation was poor in a few of the 32 livers), by
Kalamegham et al. (1979) in biopsied liver (r = -0.52) and
by Atlas et al. (1976) and Boobis et al. (1981) measuring
AHH inducibility in cultured lymphocytes (r= -0.55 and
r = -0.84). With hindsight AP was not an appropriate
choice as a potential marker drug. The above correlations
were modest because AP has three major metabolites
generated by different metabolic pathways which are likely to
be controlled by different cytochrome P-450 sub-families
(Danhof& Breimer, 1979; Boobis et al., 1981), whose relative
contribution to AP half-life varies between individuals. AP
Table II Lung tissue AHH activity in lung cancer in four controlled studies
Results (mean (s.d.))
Assay Cases Controls Smoking
status
Harris et al., chromatographic
(1977) profile of 'Similar profile for
extractable cases and controls'
metabolities (n = 9) (n = 3) Not reported
McLemore AHH activity 140 (65) 118 (78) Smokers
et al. (1978a) (fluorometric) (n = 7) (n = 7)
Oesch et al. mono-oxygenase 1.05 (0.20) 0.88 (0.37) Smokers
(1980) activity (n = 31) (n = 7)
(7-ethoxycoumarin 1.96((1.40) 0.62'(0.26) Non-smokers
as substrate) (n = 7) (n = 12)
Karki et al. AHH activity 9.7 (10.8) 15.0 (23.0) Not reported
(1987) (fluorometric) (n = 34) (n = 7)
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Table III Studies comparing aryl hydrocarbon hydroxylase (AHH) activity in lymphocytes in lung cancer cases and controls
Method ofexpressing result Number of AHH activity
(inducibility = ratio inducedl Result subjects signifilcantly
Assay method non-induced AHH; higher in
and author BP = benzo[a]pyrene) Cases Controls Cases Controls cases? Comments
Fluorometric assay
Kellermann et al.
(1973b)
Korsgaard et al.
(1977)
inducibility
inducibility
Paigen et al. AHH activity
(1977) (BP metabolites
/amount DNA)
Ward et al.
(1978)
McLemore et al.
(1977)
(1978b)
(1979)
Lieberman (1978)
Emery et al.
(1978)
Karki & Huhti
(1978)
Gahmberg et al.
(1979)
Arnott et al.
(1979) (i)
(ii)
Kouri et al.
(1982)
Karki et al.
(1987)
Radiometric assay
Guirgis et al.
(1976)
Jett et al.
(1978)
Rudiger et al.
(1980)
Macro-molecular
binding ofBP
metabolites
Jett et al.
(1979)
% high
intermediate
low
% high
intermediate
low
non-induced
induced
inducibility
inducibility % high
intermediate
low
mean ratio
AHH activity
(BP metabolities
/no. cells)
AHH activity
inducibility
AHH activity
(BP metabolities
/no. cells)
non-induced
induced
inducibility
induced
%>2.0
non-induced
induced
inducibility
inducibility % >4.0
inducibility
inducibility
AHH activity
(BP metabolities
/no. cells)
AHH activity
(BP metabolities
/no. cells
AHH activity
(BP metabolites
/amount cyto-
chrome C)
% high
non-induced
induced
inducibility
non-induced
induced
inducibility
induced
AHH activity non-induced
induced
inducibility
AHH activity induced
(BP metabolites/no. cells)
AHH activity induced
(BP metabolites/no. cells)
AHH activity induced
(BP metabolities/amount DNA)
radioactivity of BP
metabolities/amount protein
Rudiger et al. radioactivity of BP
(1980) metabolities/amount DNA
30%
66%
4%
45%
55%
0
9%
46%
45%
50 85 P<0.001 Age and smoking habit
ofcontrols not stated
22
0.12 0.13
0.24 0.57
2.0 3.2
6%
7%
19%
3.20
45
140
2.2
110
48%
7%
20%
30%
3.29
55
150
1.7
170
31%
0.26 0.33
0.53 0.56
2.1 2.4
- P<0.001 No controls, 'expected'
values from Kellerman
et al. above
12 57 No
32 57 No
36 36 No
14 15 No
73 52 P<0.05
12 12 No
Resectable cancer only,
subjects on certain
drugs excluded
resected cancer
('disease-free').
Matched for medication
Cases older
Cases smoked more
43% 21% 62 62 P<0.01 No difference in
induced AHH
5.33 4.25 43 76 P<0.05 ?Age or smoking
matched
39% 15% 92 404 P<0.01 ?Age or smoking
matched
0.06 0.08
0.40 0.42
6.4 4.9
0.24 0.36
0.81 0.87
4.06 2.90
24 24 Inducibility
higher,
P<0.01
54 122 Inducibility
higher,
P<0.05
Similar induced AHH
in cases and controls.
Inducibility ratio high
as non-induced lower in
cases
As above
0.89 0.47 21 30 P<0.001 Some technical assay
problems avoided.
Assays done blind.
Cases and controls well
matched
0.11 0.14
0.56 0.85
5.5 6.2
30 37 No Non-smoking controls
also, results similar
5.97 1.24 10 10 P<0.1 Cases smoked more
1012 1181 57 51 Controls
higher,
P<0.0O
8.38 5.50 27 27 P = 0.003 Cases older
22.4 25.1 40 48 Controls
higher,
P=0.003
7.2 6.1 27 37 No
Similar result for
non-smoking controls
Cases older
clearance or half-life thus represents a crude and variable
measure of any single cytochrome P-450 sub-family, and is
unlikely to correlate substantially with the metabolism of a
carcinogen.
Genetic control ofAP metabolism
In keeping with the observation that three different metabolic
pathways contribute variably to AP half-life, two twin studies
(Atlas et al., 1976; Vesell et al., 1971) have shown intra-pair
correlation coefficients for AP half-life to be high (>0.9) for
nine monozygous twin pairs but almost zero for nine
dizygous twin pairs, and Blain et al. (1982) found that cor-
relation of AP half-life between first degree relatives was
about as high as between spouses. Distribution of AP half-
life is wide and unimodal (Atlas et al., 1976; Kellermann et
al., 1980). All the evidence indicates that AP metabolism is
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Environmental determinants ofAP metabolism
Many environmental factors influence AP metabolism.
Indeed the main relevance of the antipyrine studies is perhaps
to illustrate how metabolic studies may be biased by factors
associated with cancer and illness, including weight loss and
changes in diet, alcohol intake and smoking. Thus AP
elimination is accelerated by smoking (Kellermann et al.,
1980; Hart et al., 1976), alcohol and caffeine (Vestal et al.,
1975), and prolonged by liver disease (Branch et al., 1973),
hypoxia (Cumming, 1976) and bed-rest (Vesell, 1979). Many
drugs and dietary factors also influence its clearance (Vesell,
1979). Elimination is slower in older than younger subjects
(Vestal et al., 1975; O'Malley et al., 1971) and in men than
women (Cumming, 1976). AP half-life is shorter in subjects
with lower body weight (Ayesh & Idle, 1985).
Evidencefor an association between AP metabolism and lung
cancer
Five studies that have compared AP clearance from saliva or
plasma in lung cases and controls are summarised in Table
IV. Ambre et al. (1977) found significantly higher clearance
in cases as did Kellermann et al. (1980) if the non-smoking
controls, rather than the smoking controls, are considered
appropriate (most cases had stopped smoking for three
months or so). Three other studies found no difference,
including Danhof (1980), who measured not only overall
clearance but also 48 h urinary excretion of four separate AP
metabolites. The two positive results could readily have been
produced by case-control differences in one or more of the
environmental factors discussed above.
Debrisoquine as a drug marker of phase I mono-oxygenation
Rationale
The anti-hypertensive drug debrisoquine is a more appropri-
ate drug marker for phase I mono-oxygenation. It has only
one important metabolite, 4-hydroxydebrisoquine (Idle et al.,
1979). The drug is partly excreted unchanged and the extent
of 4-hydroxylation before excretion, reflecting the activity of
the 4-hydroxylation pathway, varies widely between individ-
uals (Idle et al., 1979; Sloan et al., 1983), the variation being
substantially genetically determined as discussed below. Indi-
vidual metabolism of over 20 drugs and other chemicals
correlates with that of debrisoquine (Eichelbaum, 1984). This
raises the possibility of a similar correlation with the
metabolism of a carcinogen in tobacco smoke, although there
is no more specific metabolic basis for a prior hypothesis for
an association between extent of debrisoquine hydroxylation
and risk of lung cancer. Debrisoquine 4-hydroxylation is
performed by a different cytochrome P-450 enzyme from
those responsible for the mono-oxygenation of PAHs and
nitrosamines (Wolff et al., 1985).
Methodology
Both debrisoquine and its 4-hydroxy metabolite can be
measured easily and with high reproducibility (r = 0.88;
Evans et al., 1980) in urine collected for a few hours after a
single 10 mg dose. The result is expressed as the 'metabolic
ratio', the ratio of unchanged to 4-hydroxy debrisoquine (a
high metabolic ratio thus denotes little metabolism of
debrisoquine). The distribution of metabolic ratio is bimodal.
In about 90% of subjects, called extensive metabolisers,
10-99% of a 10 mg debrisoquine dose is hydroxylated before
excretion, and the metabolic ratio is distributed approx-
imately log-normally. In about 10%, called poor
metabolisers, only 1-2% is hydroxylated, making the
metabolic ratio between 10 and 200 times the average exten-
sive metaboliser value.
Genetic control ofdebrisoquine hydroxylation
Debrisoquine hydroxylation is dominated by a single gene
and poor and extensive metabolism represent two
phenotypes. Steiner et al. (1985) showed by segregation
analysis in a study of 226 subjects in 52 families that a single
major genetic locus accounted for 79% of the variation in
metabolic ratio. The smaller family study of Evans et al.
(1980) also suggested a single gene locus of major effect. The
poor metaboliser phenotype is an autosomal recessive trait,
the frequency of the recessive gene being about 0.3. Extensive
metabolisers can be either heterozygous or homozygous
dominant, metabolic ratio is lower on average in the latter,
but the two genotypes cannot be reliably distinguished by
metabolic ratio (Steiner et al., 1985). The gene has been
assigned by genetic linkage to chromosome 22 (Eichelbaum
et al., 1987), and complementary DNA has been cloned
(Gonzalez et al., 1988).
Environmental determinants ofdebrisoquine hydroxylation
Environmental determinants of debrisoquine hydroxylation,
in contrast to antipyrine, appear weak and unlikely to bias
case-control comparisons in lung cancer. Smoking, various
other environmental factors and age did not demonstrably
influence debrisoquine metabolic ratio, apart from a modest
association with coffee intake (Steiner et al., 1985). The
distribution of metabolic ratio among extensive metabolisers
is skewed to the right by certain drugs (Law et al., 1989), but
the effect did not appear to be large enough to affect the
classification of subjects into poor and extensive
metabolisers, and if it was, the bias would operate against an
association of extensive hydroxylation with lung cancer. No
drugs have been observed to be associated with a lower
metabolic ratio. The presence of a cancer may have
metabolic consequences, but no effect of other human
cancers on the phenotype test has been observed and, in
animal studies, mono-oxygenase activities are depressed by
the presence of cancer (Kato et al., 1968; Rosso et al., 1971),
Table IV Antipyrine clearance in lung cancer in five studies
Antipyrine clearance (mean (s.d.))
Lung cancer
Units cases Controls Comment
Salivary clearance
Kellermann et al. (1980) 1 h-' 2.6 (0.8) 2.0 (0.6) Non-smoking controls
(n = 57) (n = 57) (P<0.001)
2.7 (0.8) Smoking controls
(n = 59)
Plasma clearance
Ambre et al. (1977) 1 h-' 3.0 (0.7) 2.0 (0.7) (P<0.01)
(n = 7) (n = 7) Cases smoked more
Tschanz et al. (1977) 1 kg-' h-' 0.048 (0.009) 0.056 (0.007) Adjusted for body weight,
(n = 9) (n = 9) matched for medication
Danhof (1980) 1 h- 3.1 (0.6) 2.9 (1.0) Also, no difference in 48 h
(n = 10) (n = 9) excretion of4 metabolites
Ayesh & Idle (1985) ml min-' kg-' 3.0 (0.5) 2.9 (0.4) Adjusted for body weight
(n = 29) (n = 29)202 M.R. LAW
such a bias again operating against an association of exten-
sive hydroxylation with lung cancer.
Evidencefor an association between debrisoquine
hydroxylation and lung cancer
Table V lists four published studies that have measured
metabolic ratio for debrisoquine in lung cancer cases and
controls. Three studies estimated about a 5-fold increased risk
of lung cancer in extensive compared to poor metabolisers.
The estimate from the fourth was lower, and the reason for
this discrepancy is not clear. Nonetheless, all studies confirm a
higher risk of lung cancer in extensive metabolisers, that in all
studies combined is statistically highly significant (X 2 = 18,
P<0.001). Among extensive metabolisers, all studies observed
that metabolic ratios below 1.0, likely to reflect the homozy-
gous dominant phenotype, were more common in lung cancer
cases than in controls. The increased risk in extensive meta-
bolisers appears to apply particularly to squamous cell and
small cell cancer but is not statistically significant for adeno-
carcinoma (Caporaso et al., 1989).
Preliminary studies of phase II conjugation
Cancer risk is likely to be increased by low phase II
conjugating enzyme activity, since phase I intermediate com-
pounds if slowly conjugated would appear more likely to
form DNA adducts. Thus slow acetylators (homozygous
recessives) are at increased risk of occupational bladder
cancer (Cartwright et al., 1982). Acetylation is not associated
with lung cancer risk (Philip et al., 1988; Roots et al., 1988),
but conjugating enzymes involved in PAH metabolism
(Figure 1) may be. Oesch et al. (1980) found little difference
between cases and controls in conjugating enzyme activity in
lung tissue, but Seidegard et al. (1986), using peripheral
blood monocytes, found that high glutathione transferase
activity was less common in lung cancer cases than controls.
Among heavy smokers, high activity was found in 14 out of
46 cases (30%) and 38 out of 65 controls (59%) (P<0.01).
This result is preliminary, has not yet been confirmed or
refuted by others, and is prone to the various biases dis-
cussed above. Smoking for example reduces glutathione
transferase activity, so that the matching of cases and cont-
rols in recent smoking habit is critical.
Glutathione transferase activity may be dominated by a
single autosomal gene. In a study of 248 individuals
(Seidegard & Pero, 1985) activity was trimodal. Comparison
with Hardy-Weinberg expected values, and a family study,
suggested that very high (8% of the population), high (38%)
and low (54%) activity represented homozygous dominant,
heterozygous dominant and homozygous recessive genotypes
respectively.
DNA sequences as markers of lung cancer risk
Future developments in elucidating metabolic predisposition
to cancer are likely to be dominated by developments in
Table V Debrisoquinemetaboliserphenotype in lung cancercasesand
controls in four studies (EM = extensive metaboliser, PM = poor
metaboliser)
Odds ratio*
No. of No. of (95% confidence
cases controls limits)
Ayesh et al. EM 241 213 5.9 (2.0, 18)
(1984) PM 4 21
Roots et al. EM 251 240 1.7 (0.9, 3.0)
(1988) PM 19 30
Caporoso et al. EM 62 54 4.0 (0.8, 20)
(1988) PM 2 7
Law et al. EM 102 95 4.8 (1.0, 23)
(1989) PM 2 9
*Estimating relative risk of lung cancer in EM compared to PM.
recombinant DNA technology. There is much recent activity
in this area: 67 complete P-450 complementary DNA or
protein sequences were known in 1987 (Nebert & Gonzalez,
1987). Jaiswal et al. (1985) have sequenced the human P1-450
gene and shown that the quantity of P,m-RNA correlates
with induced AHH activity in human lymphocytes, but no
correlation of the PI-450 gene with risk of any cancer has yet
been published. Jaiswal et al. (1987) have also reported the
complementary DNA and protein sequences for P3-450. The
gene responsible for debrisoquine hydroxylation has been
identified as a structural gene, its complementary DNA has
been cloned and expressed in cell culture, and three different
mutant genes have been shown to give rise to defective
messenger-RNA splicing, resulting in the absence of an
immunodetectable protein in the liver (Gonzalez et al., 1988;
Skoda et al., 1988). The three mutant genes so far identified,
however, account for only about half of all poor
metabolisers.
This approach has the potential to detect single genes that
predispose to lung cancer, identifying genotype rather than
phenotype, and avoiding the biases involved in the metabolic
studies. It has as yet no advantage over the pharmacological
measure of debrisoquine hydroxylation, because it cannot
distinguish all poor metabolisers from extensive metabolisers.
Also, no probe for the conjugating enzymes is imminent.
However, 'screening' of newly sequenced P-450 genes for
association with lung cancer could greatly facilitate the
search for genetic determinants of lung cancer risk.
Public health application
Evidence for genetic predisposition to lung cancer is sought
primarily to increase our understanding of the biology of
cancer. Future public health application is unlikely. It would
be difficult to screen cigarette smokers for lung cancer risk
without at the same time implying that those without the
marker could smoke safely. Lung cancer accounts for only
about a third of all deaths attributable to smoking, and there
is no reason to suppose that the risk of coronary heart
disease and other smoking-related diseases would be different
in subjects with a marker for lung cancer risk. The harm of
such screening could outweigh the benefit.
A more limited application could lie in the selection of
low-risk workers for occupations involving risk of lung
cancer (Caporaso et al., 1989). Even this application must be
improbable. A moderate or high concentration of car-
cinogens in an industrial environment could be justified only
by the identification of a minority of the population having a
lung cancer risk of virtually zero. It would not for example
be acceptable to submit poor metabolisers of debrisoquine
(having about one-quarter the lung cancer risk of extensive
metabolisers) to such an exposure.
Conclusions
Genetic factors must contribute to lung cancer risk, since it is
the metabolites of environmental carcinogens that usually
initiate a cancer, and the metabolic pathways are genetically
controlled. The studies reviewed have examined the question
of whether significant genetically determined variation in risk
exists between individuals, and some of the evidence suggests
that it does.
The studies of familial clustering are too insensitive to be
useful, and are consistent with any interpretation from a
substantial genetic effect to no genetic effect at all; a marker
is needed to demonstrate genetic predisposition. Associations
of lung cancer with two naturally occurring antigens, the a4
Aa-ras allele and the HLA-B12 allele, may be important but
they require confirmation. The evidence linking small cell
lung cancer with the retinoblastoma (Rb) gene and with 3p
chromosomal deletions is suggestive, and there is good
evidence for genetic predisposition in at least some cases of
the rare alveolar cell carcinoma, which is not smoking-
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The numerous studies of PAH metabolism in smoking-
related lung cancer cannot collectively constitute convincing
evidence for genetic predisposition to lung cancer. Ah
dominant mice showed predisposition to PAH-induced lung
cancer, but this experimental model need not be relevant to
tobacco smoking in humans. The control of AHH activity in
humans is polygenic. The case-control studies measuring
AHH activity directly in lung tissue, one lymphocyte study in
which the cancer in cases had been resected (reducing possi-
ble bias from biological effects of cancer), and the two lym-
phocyte studies that measured DNA binding were all
negative (Tables II and III). One study has shown higher
induced AHH activity in lung cancer, but non-carcinogenic
metabolites were measured remote from the lung, and some
sources of bias could not be excluded. The one positive study
cannot outweigh the negative evidence. The association of
low conjugating enzyme activity with lung cancer in one
study is interesting, but the result may have been produced
by differences in smoking habit or other bias and requires
confirmation.
Antipyrine is not a suitable drug to investigate the genetic
determinants of lung cancer. Debrisoquine is, since 4-
hydroxylation is its only major metabolic pathway and is
dominated by a single gene. The greater risk of lung cancer
in extensive compared to poor metabolisers of debrisoquine,
confirmed in four studies, is compelling evidence for genetic
predisposition. No known environmental factor could
plausibly account for this difference, and it is in any case
uncommon for environmental factors to have so powerful an
effect on mono-oxidation as to reproduce the 10-200-fold
genetically determined difference in mean metabolic ratio
between poor and extensive debrisoquine metabolisers. Deb-
risoquine 4-hydroxylation is not associated with the mono-
oxygenation of either PAHs or nitosamines, but there could
be a shared metabolic pathway with another carcinogenic
tobacco smoke constituent. Alternatively, however, the
association with lung cancer might be explained by linkage
disequilibrium, the gene regulating debrisoquine hydroxyla-
tion being chromosomally linked to another gene that
directly affects lung cancer risk. There is thus no definite
evidence for a metabolic mechanism in genetic predisposition
to lung cancer. An ongogene for example might account for
the associations of lung cancer with both debrisoquine
metabolism and the retinoblastoma gene.
The size of the genetically determined variation between
individuals in lung cancer risk is unresolved. To propose a
genetic basis for the observation that only about 15% of
smokers develop lung cancer implies that a minority of the
population is at high risk, but there is little evidence for this.
The debrisoquine studies identify homozygous recessives,
10% of the population, at about a 4-fold reduced risk;
homozygous dominants are likely to be at higher risk than
heterozygous dominants, if the two could be reliably distin-
guished, but the difference in risk would not be large. The
studies of naturally occurring antigens suggest that about
15-25% of the population have about a 2-fold increased risk
(though an incomplete association with the antigen that
serves as a marker could dilute the real risk), and the
unconfirmed conjugating enzyme study suggests a 2.5-3-fold
increased risk in about half the population. In summary,
there is some variation between individuals in genetically
determined lung cancer risk, but as yet no evidence for
substantially increased risk in a minority of the population.
The main interest of this work is the understanding of the
biology of cancer, not public health. To screen smokers for
genetically determined lung cancer risk is impractical because
so many other diseases are also caused by smoking. An
occupational application might be feasible but this is unlikely
and certainly not imminent.
Any future metabolic studies should avoid the various
biases (mostly consequent on the illness of the cases) that
have affected the existing studies. This could be done in a
longitudinal study, metabolic activity being measured (or
blood or urine stored) in healthy smokers and a comparison
made between those who subsequently developed lung cancer
and matched controls who did not. Trell et al. (1985) have
commenced such a study measuring AHH activity. Many
subjects and long follow-up would be necessary. Alterna-
tively, the bias inherent in previous case-control studies
might be minimised by studying only long-term (say 5-year)
survivors of resection for lung cancer. Bias associated with
drugs, hospital stay and illness would be eliminated, and bias
from a metabolic effect of cancer substantially avoided. This
type of study could be performed quickly and economically.
However, developments in molecular genetics promise attrac-
tive studies that would circumvent all bias. This approach is
likely to dominate future research.
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